Results 31 to 40 of about 8,545 (210)

Molnupiravir: First Approval [PDF]

Drugs, 2022
Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback Biotherapeutics for the prevention and treatment of Coronavirus disease 2019 (COVID-19).
openaire   +2 more sources

Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat

Communications Medicine, 2023
Background The antiviral drug molnupiravir is an orally bioavailable prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC), which is used to treat coronavirus disease 2019 (COVID-19).
Chun-Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, Ling Yang, Tung-Yi Lin, Muh-Hwa Yang, Tung-Hu Tsai   +6 more
doaj   +1 more source

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19

Viruses, 2023
Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in animal models of COVID-19, prompting clinical trials, in which initial results indicated a significant effect against the disease.
Henrik Berg Rasmussen, Peter Riis Hansen
doaj   +1 more source

Molnupiravir: a new hope in the treatment of COVID-19 [PDF]

, 2022
Coronavirus disease-19 (COVID-19), a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing pandemic since its first emergence in Wuhan, China in December 2019.1 Most of the people with COVID-19 ...
Paudel, Rama
core   +2 more sources

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrierResearch in context

EBioMedicine, 2023
Summary: Background: Molnupiravir is an orally bioavailable prodrug of the nucleoside analogue β-D-N4-hydroxycytidine (NHC) and is used to treat coronavirus disease 2019 (COVID-19).
Chun-Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, Tung-Yi Lin, Muh-Hwa Yang, Jeffrey W. Dalley, Tung-Hu Tsai   +6 more
doaj   +1 more source

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry [PDF]

, 2022
Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized for underlying diseases not related to COVID-19. We conducted a retrospective analysis regarding molnupiravir therapy in patients with SARS-CoV-2 infection ...
Boglione, Lucio, Borrè, Silvio, Bosio, Roberta, Brusa, Maria Teresa, Corcione, Silvia, De Rosa, Francesco Giuseppe, Fornari, Valentina, Lupia, Tommaso, Pinna, Simone Mornese, Rizzello, Barbara, Shbaklo, Nour, Torresan, Stefano   +11 more
core   +2 more sources

New analytical method development and validation for estimation of molnupiravir in bulk and tablet dosage form by RP-HPLC method [PDF]

Cellular, Molecular and Biomedical Reports, 2023
A new simple, selective, rapid, precise reversed-phase high-performance liquid chromatography method has been developed and validated for the estimation of Molnupiravir in bulk and its pharmaceutical dosage form.
Gandu Sravanthi, Kumara Gandla, Lalitha Repudi   +2 more
doaj   +1 more source

Molnupiravir and Its Antiviral Activity Against COVID-19

Frontiers in Immunology, 2022
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden.
Lili Tian, Zehan Pang, Maochen Li, Fuxing Lou, Xiaoping An, Shaozhou Zhu, Lihua Song, Yigang Tong, Huahao Fan, Junfen Fan   +9 more
doaj   +1 more source

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. [PDF]

, 2023
The antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals ...
Ahmad, Shazaad, Buadi, Amanda, Bullock, Katie, Byrne, Rachel, Cameron, David, Chiong, Justin, Cubas Atienzar, Ana, Darbyshire, Janet, Donovan-Banfield, I'ah, Downs, Nichola, Edwards, Christopher J., Edwards, Thomas, Ewings, Sean, FitzGerald, Richard, Fletcher, Tom, Freedman, Andrew, Greenhalf, William, Griffiths, Gareth, Hadjiyiannakis, Dennis, Hale, Colin, Hayden, Fred, Hiscox, Julian A., Holman, Wayne, Jacobs, Michael, Jaki, Thomas, Jones, Jayne, Julious, Stevan, Khoo, Saye H., Knight, Richard, Knox, Emma, Lalloo, David, Lavelle-Langham, Lara, Lorch, Ulrika, Lucas, Amy, Lyon, Rebecca, Middleton, Calley, Mozgunov, Pavel, Northey, Josh, Painter, Wendy, Paton, Nicholas, Periselneris, Jimstan, Reynolds, Helen, Rowland, Tim, Saunders, Geoffrey, Shaw, Victoria, Song, Anna, Tetlow, Michelle, Walker, Lauren, Williams, Chris, Woods, Christie   +49 more
core   +2 more sources

Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis

Antibiotics, 2023
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is unknown. The goal of the current meta-analysis was to compare the real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 during the ...
Chienhsiu Huang, Tsung-Lung Lu, Lichen Lin   +2 more
doaj   +1 more source